文献速递淋巴瘤

分子背景界定双蛋白表达弥漫大B细胞淋巴瘤的结局

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

该研究在181例原发弥漫大B细胞淋巴瘤(DLBCL)患者中分析BCL2、BCL6和MYC的易位与蛋白表达,并与突变、转录组和临床数据关联,在独立数据集中验证关键发现。双蛋白表达(DPE)源于异质性分子背景,呈亚型依赖模式;DPE独立于国际预后指数(IPI)和细胞起源定义预后实体,与TP53缺失协同恶化生存。

要点

  • DPE DLBCL源于异质性分子背景,呈生发中心B细胞(GCB)与活化B细胞(ABC)亚型依赖模式。
  • DPE独立于IPI和细胞起源定义预后实体,与TP53缺失协同产生不良生存影响。
  • DPE DLBCL中TP53缺失与化疗难治性疾病相关,其他DLBCL中未见与生存相关。

核心结论

  • 研究定义了DLBCL中双蛋白表达的分子特征,并识别出临床可行的结局预测因素。
  • 鉴于BCL2、BCL6、MYC和TP53新兴的分类学意义,研究为DLBCL基因组分类提供进一步深度和验证。

研究设计与样本

  • 分析181例原发DLBCL患者的BCL2、BCL6和MYC易位及蛋白表达,并与综合突变、转录组和临床数据关联。
  • 在独立数据集中验证关键发现。

主要发现

  • BCL2结构变异呈亚型特异性,并特异性增加BCL2表达。
  • MYC失调的分子解剖显示与其他淋巴瘤驱动因素(包括TP53缺失)相关,并具有独特基因表达谱。
  • 在GCB DLBCL中,MYC和BCL2位点同时改变产生大多数DPE DLBCL;在ABC DLBCL中同时改变不常见。
  • DPE DLBCL独立于IPI和细胞起源定义预后实体,与TP53缺失协同产生不良生存影响。
  • DPE DLBCL中TP53缺失与化疗难治性疾病相关,其他DLBCL中未见与生存相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Concomitant deregulation of MYC and BCL2 comprises clinically significant, yet poorly characterized biological high-risk feature in diffuse large B-cell lymphoma (DLBCL). To interrogate these lymphomas, we analyzed translocations and protein expression of BCL2, BCL6, and MYC; correlated the findings with comprehensive mutational, transcriptomic, and clinical data in 181 patients with primary DLBCL; and validated the key findings in independent data sets. Structural variations of BCL2 were subtype-specific and specifically increased BCL2 expression. Molecular dissection of MYC deregulation revealed associations with other lymphoma drivers, including loss of TP53, and distinctive gene expression profiles. Double protein expression (DPE) arose from heterogeneous molecular backgrounds that exhibited subtype-dependent patterns. In the germinal center B-cell (GCB) DLBCL, concurrent alterations of MYC and BCL2 loci gave rise to the majority of DPE DLBCLs, whereas among the activated B-cell (ABC) DLBCLs, concurrent alterations were infrequent. Clinically, DPE DLBCL defined a prognostic entity, which was independent of the International Prognostic Index (IPI) and cell of origin, and together with the loss of TP53 had a synergistic dismal impact on survival. In the DPE DLBCL, the loss of TP53 was associated with a chemorefractory disease, whereas among the other DLBCLs, no correlation with survival was seen. Importantly, BCL6 translocations identified non-GCB lymphomas with favorable BN2/C1-like survival independent of IPI and concurrent DPE status. Taken together, our findings define molecular characteristics of the DPE in DLBCL, and recognize clinically feasible predictors of outcome. Given the emerging taxonomical significance of BCL2, BCL6, MYC, and TP53, our findings provide further depth and validation to the genomic classification of DLBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Meriranta L, Pasanen A, Alkodsi A, et al. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma. Blood Adv. 2020. PMID: 32780847. doi:10.1182/bloodadvances.2020001727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。